Antipodes Partners’s Relmada Therapeutics RLMD Stock Holding History
Bought
Maintained
Sold
Other funds holding RLMD
JT
SCM
VA
SSC
JHC
O
Antipodes Partners's RLMD Position: Q2 2026 in Review
Antipodes Partners reduced its Relmada Therapeutics (RLMD) stake by 20% in Q2 2026, selling an estimated $4.34K and leaving 2,414 shares worth $16.7K. The position accounts for ﹤0.01% of the portfolio, ranked #128.
Antipodes Partners first reported a position in RLMD in Q1 2026 and has held it in 2 quarters since. The position peaked at $21.1K in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.
- Antipodes Partners held 2,414 shares of Relmada Therapeutics worth $16.7K as of Q2 2026.
- Antipodes Partners sold 621 Relmada Therapeutics shares in Q2 2026, an estimated $4.34K.
- Relmada Therapeutics made up ﹤0.01% of Antipodes Partners's portfolio in Q2 2026, its #128 holding.
- Antipodes Partners first reported a position in Relmada Therapeutics in Q1 2026 and has held it in 2 quarters since.
- Antipodes Partners's Relmada Therapeutics position peaked at $21.1K in Q1 2026.
- 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.
Based on Antipodes Partners's 13F filing for Q2 2026, filed 6 Aug 2026.